Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone for developmental stuttering in Persian-speaking children
IRCT20240527061909N1Phase 3Completed
- Sponsor
- Babol University of Medical Sciences
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of risperidone in childhood-onset fluency disorder (COFD), sponsored by Babol University of Medical Sciences. Started Aug 2024; status: completed.
02
Drugs
risperidone
03
Conditions
childhood-onset fluency disorder (COFD)
Beyond the preview
Go deeper on IRCT20240527061909N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240527061909N1.